Friday, September 04, 2020 12:48:39 AM
Pre-Trial, Trial, and Post Trial Briefs! 3x's they let Mori go on by.
Can't blame Due: She decided primarily on Mori.
Can't blame Singer: He cannot introduce old or new evidence and Novo (case Precedent) allowed SC's in 'out of order'.
Cant blame the Appealant Judges: They can't allow new or old evidence and Novo (case Precedent) allowed SC's 'out of order'...
Amarin's 1st Legal Team completely dropped the ball 100%.
Even the Generics Lawyer said in his OA in closing (in similar words): They just want to go back and look at old evidence that even their legal team let in and didn't challenge!
On a whole separate note:
It is just unbelievable to me that once the 1st trial is done, you cannot go back and reverse a case on Appeal with corrected evidence that was intentionally edited to favor the Defendants.
I've said a few times there is a potential path that was mentioned in Novos closing Summary by the Appealant Judges that said had (bad) evidence been used that was intentionally compromised or used in favor of correct evidence, a "But/For" review could have occurred. Novo (who like Amarin lost) pointed out a problem with evidence that they felt compromised the Trial. (Their appeal was also based on the mishandled SC's.) THE JUDGES REVIEWED THE BAD EVIDENCE!!! The Judges said in closing that the issue with the evidence was not enough to change the Obviousness determination YET it certainly would have in ours! Had Singer noted this and expressed it when asked how our case mirrored or did not mirror Novo, he could have said it was similar YET "BUT/FOR" the bad evidence introduced by the Defendants, this case would have been different. In Novo, the Judges said there was no bad evidence that would have changed the outcome! This potentially would have given our Judges something to grab on to seeing it was allowed in Novo. Dyke or Reyes said: There are cases already out there that we have to follow (such as Novo that I believe made it to the US Supreme Court of Appeals which is why they used it as the backbone of their decision - it set a Precedent regarding how SC's no matter how they are viewed must be strong enough to over-take an Obviousness decision - unless you have "But/For" evidence that they implied would have been considered in Novo.) Singer "hoped" they would review it with the understanding that the Judges did not have to or maybe aren't allowed to in an Appeals case - yet the Summary in Novo appears to allow it... (Maybe Amarin can use this in their upcoming appeal...)
Back to our 1st Legal Team:
How could they have not challenged and beat the daylights out of every single shred of evidence that the Generics threw out??? We're they sleeping that day when Mori was presented? Pre-trial, Trial, and Post Trial??? Yet cropped evidence made it thru unchallenged???
Where did it all start!?!
That is 100% where we lost the case!
Billions and Billion lost over mis-handled evidence by our legal team in the original trial!
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM